712 North Inc. Announces Landmark Publication of OMA1 High-Throughput Screening Platform

October 21, 2021 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today the publication of a groundbreaking study entitled “OMA1 High-Throughput Screen Reveals Protease Activation by Kinase Inhibitors” in the prestigious journal ACS Chemical Biology.

“This is a major milestone for our company and the field of mitochondrial research,” said Dr. Marcel V. Alavi, CEO of 712 North. “OMA1 is an exceptionally challenging drug target, and I am not aware of anyone who has successfully drugged this protease until now. This platform allows us to finally interrogate this pathway at scale.”

This research was supported by the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), reflecting the potential impact of OMA1 modulation on age-related diseases.

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.